Trial reportCell and tissue banking2026
Early clinical outcomes of keratoplasty using donor corneas preserved in sinasol (ZiSol) versus optisol-GS.
Trial report in Cell and tissue banking, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To compare early postoperative outcomes of penetrating keratoplasty (PKP) and Descemet stripping automated endothelial keratoplasty (DSAEK) using donor corneas preserved in ZiSol (formerly Sinasol) versus Optisol-GS. Prospective, double-masked, randomized clinical trial. Ninety-seven eligible eyes undergoing PKP or DSAEK were randomized to receive corneas preserved in ZiSol or Optisol-GS at 4 °C. Preoperative assessments included uncorrected distance visual acuity (UDVA) and corneal edema grading. Postoperative visits at 1 week, 1, 3, and 6 months assessed UDVA, corrected distance visual acuity (CDVA), corneal edema grading, re-epithelialization, microbial keratitis, suture-related complications, and graft attachment (for DSAEK). The PKP cohort comprised 32 ZiSol and 20 Optisol-GS cases; the DSAEK cohort included 13 ZiSol and 23 Optisol-GS cases. At 6 months, mean CDVA was 0.52 ± 0.28 LogMAR (ZiSol) versus 0.41 ± 0.13 LogMAR (Optisol-GS) after PKP (P = 0.132) and 0.47 ± 0.26 versus 0.63 ± 0.40 LogMAR after DSAEK (P = 0.272). Final graft clarity was achieved in 93.3% (ZiSol) and 95.3% (Optisol-GS) of recipients. Complete re-epithelialization by day 7 occurred in 96.9% versus 100% of PKP cases (P > 0.999). Microbial keratitis occurred in 6.3% (ZiSol) and 0% (Optisol-GS) after PKP (P = 0.517). Complete graft attachment after DSAEK occurred in 100% (ZiSol) versus 87% (Optisol-GS) (P = 0.288). Early postoperative outcomes of PKP and DSAEK using ZiSol-preserved donor corneas were statistically comparable to those with Optisol-GS. ZiSol appears to be a safe, effective, and locally accessible alternative for mid-term hypothermic storage in resource-limited settings.
Indexed as
Identifiers
42436351What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.